Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
EOD close · as of 2026-09-14
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.3M 100.0% | $57.7M 100.0% | $84.5M 100.0% | $75.7M 100.0% | $68.8M 100.0% | $45.6M 100.0% | $36.6M 100.0% | $26.9M 100.0% | $17.2M 100.0% | $16.5M 100.0% |
| Cost of Revenue | $20.9M 33.1% | $20.9M 36.2% | $22.9M 27.1% | $30.8M 40.6% | $32.1M 46.6% | $14.6M 32.0% | $10.5M 28.8% | $6.1M 22.8% | $3.7M 21.2% | $790K 4.8% |
| Cost of Products | — | — | — | — | — | — | — | — | $3.7M 21.2% | $790K 4.8% |
| Research & Development | — | — | $106.1M 125.5% | $134.9M 178.1% | $128.9M 187.3% | $64.1M 140.6% | $81.3M 222.0% | $87.4M 325.1% | $48.3M 280.2% | $35.1M 213.2% |
| Selling, General & Admin | $96.4M 152.4% | $87.7M 152.1% | $91.0M 107.7% | $113.7M 150.1% | $86.8M 126.2% | $61.2M 134.1% | $55.6M 151.8% | $53.4M 198.5% | $50.9M 295.1% | $28.2M 171.3% |
| Total Operating Expenses | $133.5M 211.0% | $168.1M 291.4% | $226.9M 268.4% | $279.3M 368.8% | $257.3M 374.1% | $139.9M 306.7% | $147.4M 402.5% | $146.9M 546.4% | $107.0M 620.7% | $82.2M 498.7% |
| Operating Income | -$70.2M -111.0% | -$110.4M -191.4% | -$142.3M -168.4% | -$203.6M -268.8% | -$188.5M -274.1% | -$94.3M -206.7% | -$110.8M -302.5% | -$120.0M -446.4% | -$89.8M -520.7% | -$65.7M -398.7% |
| Interest Expense | $10.1M 16.0% | $13.5M 23.5% | $15.3M 18.1% | $12.5M 16.5% | $15.3M 22.3% | $15.3M 33.6% | $11.8M 32.3% | — | $5.9M 34.0% | $3.7M 22.4% |
| Interest & Investment Income | $2.5M 3.9% | $2.7M 4.7% | $3.0M 3.6% | $1.4M 1.8% | $649K 0.9% | $1.5M 3.3% | $2.6M 7.0% | $1.1M 4.1% | $819K 4.7% | $298K 1.8% |
| Other Income (Expense), net | $36.7M 58.0% | -$10.2M -17.6% | -$11.3M -13.4% | -$9.9M -13.1% | $24.2M 35.2% | -$8.6M -18.8% | $9.2M 25.0% | -$10.8M -40.2% | -$7.7M -44.7% | -$5.6M -33.9% |
| Pretax Income | -$33.5M -53.0% | -$120.5M -209.0% | -$153.6M -181.8% | -$213.5M -281.8% | -$164.4M -238.9% | -$102.8M -225.6% | -$101.7M -277.5% | -$130.8M -486.6% | -$97.5M -565.5% | -$71.3M -432.6% |
| Income Tax Expense | -$620K -1.0% | $312K 0.5% | $521K 0.6% | $449K 0.6% | $473K 0.7% | $500K 1.1% | $0 0.0% | $0 0.0% | $1.5M 8.8% | $0 0.0% |
| Net Income | $37.0M 58.5% | $21.0M 36.4% | $31.0M 36.7% | -$86.6M -114.3% | -$64.7M -94.1% | -$46.5M -102.0% | -$40.0M -109.1% | -$84.1M -313.0% | -$66.9M -387.8% | -$55.1M -334.3% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | — | — | — | — | — |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 27.9M | 20.8M | 8.1M | 5.9M | 81.7M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | 27.9M | 20.8M | 8.1M | 5.9M | 81.7M | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $664000 dividends + $0 buybacks = $664000 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $79M covers all $15M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2012-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~18.5% on $54M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
No trend data available for this metric.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-14
No material risks flagged.
Where each multiple sits in its own 14-yr range · 14th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 22.8 | 28.8 | 32.0 | 46.6 | 40.6 | 27.1 | 36.2 | 33.1 |
| R&D | 325.1 | 222.0 | 140.6 | 187.3 | 178.1 | 125.5 | — | — |
| SG&A | 198.5 | 151.8 | 134.1 | 126.2 | 150.1 | 107.7 | 152.1 | 152.4 |
| Operating Income | -446.4 | -302.5 | -206.7 | -274.1 | -268.8 | -168.4 | -191.4 | -111.0 |
| Income Tax | 0.0 | 0.0 | 1.1 | 0.7 | 0.6 | 0.6 | 0.5 | -1.0 |
| Net Income | -313.0 | -109.1 | -102.0 | -94.1 | -114.3 | 36.7 | 36.4 | 58.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on FBIO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.27T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $999.5B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $641.1B | 24.1× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $463.1B | 110.9× | 33.1× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.4B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $347.5B | 29.0× | 20.1× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $254.0B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $231.3B | 34.6× | 30.0× | 5.2× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $205.6B | 26.8× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $181.7B | 21.6× | 19.9× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $179.5B | 27.7× | 19.4× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $143.7B | 40.3× | 29.8× | 5.8× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $134.2B | 48.0× | 36.9× | 13.3× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $132.0B | 33.9× | 28.9× | 11.0× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $130.4B | 18.5× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| LGVN | $121.6B | — | — | 101442.6× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $121.4B | 68.7× | 12.2× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| MDT | $120.1B | 25.1× | 12.7× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| SYK | $107.7B | 33.6× | 18.5× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $106.2B | 23.7× | 16.7× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $95.6B | 15.0× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $93.6B | 16.8× | 15.8× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $83.0B | 19.1× | 19.9× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| FBIO | $79M | — | — | 1.3× | 9.7% | 66.9% | 10.8% | 13.7% | 6.5% | -0.8× | 51 |
Peers = companies sharing FBIO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.